Patrick Yudez
Medical · Henderson, NVNPI 1366152126
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 9.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,536 and has fallen 94.6% since, to $192 in 2025.
Across 318 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$566
- Lilly USA, LLC$500
- Sanofi-aventis U.S. LLC$491
- Xeris Pharmaceuticals, Inc.$484
- Bayer$454
- Boehringer Ingelheim$407
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,139100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $566 |
| Lilly USA, LLC | 37 | $500 |
| Sanofi-aventis U.S. LLC | 13 | $491 |
| Xeris Pharmaceuticals, Inc. | 28 | $484 |
| Bayer | 35 | $454 |
| Boehringer Ingelheim | 20 | $407 |
| AstraZeneca(2 entities) | 16 | $394 |
| Radius Health, Inc. | 18 | $382 |
| Mannkind Corporation | 16 | $322 |
| Amgen | 14 | $254 |
| AbbVie | 11 | $237 |
| Recordati_rare_diseases_inc. | 9 | $215 |
| Almatica Pharma LLC | 9 | $176 |
| Kyowa Kirin, Inc. | 7 | $173 |
| IBSA Pharma Inc. | 8 | $150 |
| Dexcom, Inc. | 7 | $137 |
| Corcept Therapeutics | 6 | $116 |
| Amphastar Pharmaceuticals, Inc. | 6 | $96 |
| Esperion Therapeutics, Inc. | 4 | $78 |
| Averitas Pharma Inc. | 4 | $76 |
| Novartis | 2 | $58 |
| Daiichi Sankyo Inc. | 3 | $57 |
| Ascensia Diabetes Care US Inc. | 3 | $50 |
| Pfizer | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $30 |
| Tolmar, Inc. | 2 | $30 |
| Rhythm Pharmaceuticals, Inc. | 1 | $29 |
| Antares Pharma, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Medtronic | 1 | $20 |
| Chiesi USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$253
How this compares
$6,139 in reported general payments places this provider in the 85th percentile of 250 medical providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 172 | $191,411 |
| MounjaroTirzepatide | 89 | $112,126 |
| JardianceEmpagliflozin | 71 | $81,249 |
| TrulicityDulaglutide | 35 | $41,667 |
| FarxigaDapagliflozin Propanediol | 47 | $37,694 |
| RybelsusSemaglutide | 29 | $31,440 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $20,070 |
| TradjentaLinagliptin | 20 | $18,693 |
| Cinacalcet Hcl | 34 | $17,744 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $16,799 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $15,723 |
| Gvoke Hypopen 2-PackGlucagon | 21 | $12,860 |
| Novolog FlexpenInsulin Aspart | 44 | $9,947 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $6,546 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $5,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $566 | $222,851201 claims |
| Lilly USA, LLCMounjaro, Trulicity | $500 | $153,793124 claims |
| Boehringer IngelheimJardiance, Tradjenta | $407 | $99,94291 claims |
| AstraZenecaFarxiga | $394 | $37,69447 claims |
| AbbVieSynthroid, Armour Thyroid | $237 | $3,81069 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 medical providers in Nevada.
Other medical in Henderson
- Payton CerdaHenderson$9K
- Sururat CoulibalyHenderson$8K
- Vanvan NguyenHenderson$7K
- Eric HaralsonHenderson$5K
- Kristine-Gem EstrellaHenderson$5K
- Elena ZalanHenderson$4K
- Jessica GdovinHenderson$3K
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.